TXN-A / Txinno Biosci - LARVOL DELTA

Discovery and characterization of TXN-A: A first-in-class, orally bioavailable ULK1 degrader with high selectivity and potency for TNBC treatment (AACR 2026) - "In this study, we developed TXN-A, a first-in-class highly selective, potent and orally bioavailable ULK1 degrader to overcome chemoresistance and enhance anti-tumor therapeutic efficacy of Paclitaxel (PTX) in TNBC. Autophagosome formation was measured using the Cyto-ID. This study with TXN-A, a first-in-class highly selective, potent and orally bioavailable ULK1 degrader, demonstrated that it interferes with autophagy-dependent survival in TNBC cells, resulting in enhancing the anti-tumor effects of chemotherapy. Selective ULK1 degradation, in combination with PTX, is a promising therapeutic approach for TNBC. Synergistic anti-tumor activity of TXN-A with taxanes suggests potential clinical development for refractory and resistant TNBC patients."

Late-breaking abstract • Oncology • Triple Negative Breast Cancer • CRBN • ULK1